All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond the Company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The tests will be based on the Company's Target System, a platform that is centered on an analyzer and its innovative flow through test cartridges. Parallax's focus is on tests that diagnose and/or monitor medical conditions, and combines innovative technologies that will provide accessible, practical and rapid point of care in vitro diagnostics. The Company owns a line of point of care diagnostic tests on a single proprietary platform, and is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians. Parallax is a bio-medical company focused on infectious diseases. Parallax Health Sciences, Inc., with offices in Santa Monica, CA and Boston, MA, is a fully reporting Nevada corporation (OTCQB: PRLX). RoxSan provides individualized compounding for pain management, medications for infertility treatments, as well as full-service prescription management. RoxSan Pharmacy, established over 60 years ago, is a compound pharmacy headquartered in Beverly Hills, California, and licensed in over 40 US states. The addition of RoxSan to the Parallax family provides synergies with our efforts to offer patients personalized medicine for both the diagnosis and treatment of medical conditions." The fertility business is growing and provides a differentiated service. In addition to the compounding business, RoxSan is one of the largest providers of fertility medicines. RoxSan is a leading compounding pharmacy specializing in pain management therapies. Parallax's CEO, Michael Redmond, said, "Parallax is fortunate to team with such an outstanding organization as RoxSan. In 2014, RoxSan had unaudited gross revenues in excess of $40M, and EBITDA of approximately $10M. The Note bears interest at a rate of 6% per annum and matures in three (3) years. The terms of the Purchase Agreement include a secured promissory note (the "Note") issued to the Seller, in the amount of $20.5 million. The transaction is immediately accretive to Parallax. The Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares, Its Assets and Inventory (the "Purchase Agreement") was executed on August 13, 2015. ("Parallax" or the "Company") (OTCQB: PRLX), is pleased to announce the completion of the acquisition of RoxSan Pharmacy, Inc., a privately held California corporation ("RoxSan") located in Beverly Hills, CA. SANTA MONICA, CA / ACCESSWIRE / Aug/ Parallax Health Sciences, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |